Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer - Experience from a prematurely closed phase II study [5]

Lung Cancer

Volumn 45, Issue 1, 2004, Pages 131-132

  Raez, Luis E ^a   Rosado, Manuel F ^a   Santos, Edgardo S ^a   Reis, Isildinha M ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; IRINOTECAN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EMPYEMA; EPIDURAL ABSCESS; HUMAN; KAPLAN MEIER METHOD; LETTER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

EID: 2942545856     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.01.008     Document Type: Editorial

References (4)

1. Masuda N., Negoro S., Kudoh S., Sugiura T., Nakagawa T., Saka H., et al. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J. Clin. Oncol. 18:2000;2996-3003
2. Adjei A., Argitis A., Murren I.R. Docetaxel and Irinotecan, combination, in the treatment of non-small cell lung cancer. Oncology. 26(Suppl 167):1999;32-40
3. Murren J.R., Blum K., Gallipoli M., McKeon A., Rich R. Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule. Oncology (Huntngt). 15(1 suppl 1):2001;25-30
4. Satouchi M., Takada Y., Takeda K., Yamamoto N., Negoro S., Nakagawa K., et al. Randomized phase II study of docetaxel plus cisplatin versus docetaxel plus irinotecan in advanced non-small cell lung cancer (NSCLC): a west Japan thoracic oncology group (WJTOG) study. Proc. Am. Soc. Clin. Oncol. 20:2001;1312a